Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Revestimiento cerámico nanoestructurado liberador de fármacos muy adherente


Oferta Tecnológica
Una pyme suiza especializada en sistemas médicos ha desarrollado un revestimiento cerámico nanoestructurado muy adherente para diferentes sustratos. Su estructura anisotrópica permite crear reservas para almacenar un medicamento cubierto por una capa que controla la administración en el tiempo. La empresa busca una compañía especializada en tecnologías médicas interesada en la cartera de patentes para continuar con el desarrollo y aplicar la tecnología en varios productos. El objetivo es establecer acuerdos de licencia.


Highly adherent nano-structured ceramic drug eluting coating
The technology, developed by a Swiss medical systems SME, is a highly adherent nano-structured ceramic coating that can be used on various substrates. Its anisotropic structure permits the creation of reservoirs to store a drug covered by layer controlling release over time.
The company is looking for a partner, e.g. a medical technology company, who would be interested in the patent portfolio to further develop the technology and apply it to various products. License agreement is sought.
Ceramic coatings for drug storage and release:
The use of ceramic coatings as an alternative to store drugs at and release them from the surface of implants has been contemplated for several years. Ceramics are known for their biocompatibility and they have been perceived as an excellent candidate that could avoid the toxicity of polymers. However, a major issue with ceramics is their very high brittleness. For devices which undergo large deformation during the implantation procedure (e.g. stents), this is seen as a major drawback. The only way to avoid such dramatic issue is to use very thin layers of ceramic. But the use of these very thin layers is creating an additional issue: the trade-off between drug loading capacity and elution speed.
In order to tackle this new issue, the best solution would be to create large cavities. Enough drug could then be loaded into these cavities to cover the needs of the therapy. The problem with such large cavities is the impossibility to maintain a release over a long period of time: the drug is flushed away very rapidly.
Another way to increase the duration of the release is to create a nano-porosity into the coating. The elution of the drug in such a coating is still controlled by its dissolution rate, but also, and mostly, by its diffusion rate through the created nano-porous layer. By tailoring the pores one can adapt the diffusion rate of any molecule. The major issue with such coating is the loading capacity: the drug is released according to the needs, but there is not enough drug for the treatment.

Nanoporous coating:
The solution proposed and covered by this patent portfolio of a Swiss medical systems company is an anisotropic, hierarchical, nano-porous coating (NanoCoating), combining the advantages of both, micro- and nano-porosities: micro-meter size reservoirs are buried into a nano-porous ceramic layer. In this way, enough drug can be loaded into the reservoirs. It will be released over a few weeks and independently of its chemical composition, as the release profile will be mostly driven by the diffusion properties through a nano-porous layer.
The process developed to produce this coating also allows the manufacturing of highly adhesive coatings. Their nano-structuration allows them to comply with the substrate when it is deformed without any delamination.

Drug release:
For the active coating version, the NanoCoating contains a structural element and an element that is sensitive to enzymes produced by a given type of cells (the substrate). Enzymes are known to be highly specific. For example, they can break substrates in two or more parts. In this coating the substrate is mixed to the structural material and the drug is embedded in such mixture. When the target cell (or bacteria) is present, it releases specific enzymes that will break the substrate, as a consequence destroy the coating, and liberate the drug. As soon as the cell disappears, enzymes are no more released and elution stops.

The Swiss company is seeking partners, e.g. manufacturer of medical devices, that are interested to license or acquire the patent portfolio, to further develop the technology to be used in various products and to commercialize them . Manufacturer of coatings from different industries where high performances are expected, e.g. aerospace, energy or construction materials might also be interested.
Advantages and Innovations:
The innovation of this coating lies in its constituting materials.
- For the highly adhesive anisotropic coating, the material is done of randomly packed nanoparticles. The nanoporosity controls the elution of the drug and limits the propagation of cracks in case of substrate deformation.
- Possibility to tune the drug elution duration by controlling the path through the layer or size modification of the pores.
- Substrate deformation creates mechanical constrains within the coating. For hard materials such as ceramics, cracks start to form and progress rapidly. The adherence force is not able to withstand the shear stress induced at the substrate-coating interface and delamination occurs. Nanomaterials avoid both effects. The ceramic keeps a relative elasticity and the crack stress dissipates thanks to a rearrangement of the nanoparticles. The substrate-coating interface is made of a multitude of small domains. The shear stress on each of these domains will never be high enough to outmatch the adhesive force. The coating does not delaminate.
- Existing solutions have the disadvantage of passiveness, i.e. once implanted into a tissue, the drug present in the coating immediately starts to be released. The elution profile is defined by various physico-chemical parameters. In one of its version, the presented NanoCoating is made of a structural material and an active agent that allows the drug release only when in contact with the targeted tissue or cells. The coating contains a sort of switch system that allows it to be active only when required.
Stage of Development:
Under development/lab tested
Patent(s) applied for but not yet granted,Patents granted,Exclusive Rights
CommeR Statunts Regarding IPR Status:
Patent portfolio: 7 patents families, 18 granted national extensions, 11 pending applications

Partner sought

Type and Role of Partner Sought:
The specific area of activity of the partner:
Manufacturer of medical devices, e.g. stents or surgical implants. The technology may have a large variety of uses. Medical implants with active coating are obvious applications: orthopedic implants with elution of bone growth factors or antibiotics to limit potential postoperative infections, cardiovascular implants such as drug eluting stents or dental applications.
Manufacturer of coatings from different industries where high performances are expected, e.g. aerospace, energy, construction materials, materials science.

The tasks to be performed by the partner sought:
Finalization of the development, application in various commercial fields and commercialization of the newly developed product.


Type and Size of Client:
Industry SME 50-249
Already Engaged in Trans-National Cooperation:
Languages Spoken:


Technology Keywords:
06001024 Biomateriales médicos
06001017 Cirugía
02007024 Nanomaterials
02002002 Recubrimientos
06001013 Tecnología médica / ingeniería biomédica